Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9068117 | 1.00 | EPHX2 (0.65) | EPHX2CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL2235416 | 1.00 | EPHX2 (0.65) | EPHX2CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL30658134 | 1.00 | EPHX2 (0.65) | EPHX2CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30406514 | 0.99 | EPHX2 (0.64) | EPHX2CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL2238920 | 0.96 | EPHX2 (0.70) | EPHX2CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL2238928 | 0.96 | EPHX2 (0.70) | EPHX2CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL1769376 | 0.91 | EPHX2 (0.69) | EPHX2CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL1769371 | 0.91 | EPHX2 (0.69) | EPHX2CYP2C9CYP2C19KMT2ASMN1; SMN2 | |
| SCHEMBL24130547 | 0.85 | HDAC1 (0.58) | EPHX2KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL345305 | 0.85 | HDAC1 (0.58) | EPHX2KMT2ASMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388669-A1 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | Wang, Jieyi (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250263504-A1 | BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-21 | — | — | US | disclosed |
| US-12240918-B2 | Bispecific antibodies against plasma kallikrein and factor XII | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-03-04 | — | — | US | disclosed |
| WO-2025024646-A1 | MULTI-SPECIFIC ANTIBODIES INTEGRATING DUAL IMMUNE MODULATING MOIETIES AND USES THEREOF IN IMMUNOTHERAPY | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2025-01-30 | — | — | WO | disclosed |
| EP-4466020-A2 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | Lyvgen Biopharma Holdings Limited (KY) | 2024-11-27 | — | — | EP | disclosed |
| CN-114316061-B | Bispecific antibodies against plasma kallikrein and factor XII | 武田药品工业株式会社 | 2024-11-01 | — | — | CN | disclosed |
| US-20240218069-A1 | BI-SPECIFIC ANTIBODIES COMPRISING ANTI-B7H3 BINDING MOLECULES | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2024-07-04 | — | — | US | disclosed |
| US-20230406950-A1 | BI-SPECIFIC ANTIBODIES COMPRISING ANTI-CD137 BINDING MOLECULES | LYVGEN BIOPHARMA HOLDINGS LIMITED (KY) | 2023-12-21 | — | — | US | disclosed |
| CN-117015399-A | Bispecific antibodies comprising anti-CD 137 binding molecules | 礼进生物医药科技（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-4243869-A1 | BI-SPECIFIC ANTIBODIES COMPRISING ANTI-CD137 BINDING MOLECULES | Lyvgen Biopharma Holdings Limited (KY) | 2023-09-20 | — | — | EP | disclosed |
| EP-2192185-A1 | MUTANT PYRROLYSYL-TRNA SYNTHETASE, AND METHOD FOR PRODUCTION OF PROTEIN HAVING NON-NATURAL AMINO ACID INTEGRATED THEREIN BY USING THE SAME | Riken (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2010-01-07 | — | — | US | disclosed |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2010-01-07 | — | — | US | disclosed |
| WO-2009136352-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2009-11-12 | — | — | WO | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008056346-A2 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-05-15 | — | — | WO | disclosed |
| EP-0998940-A1 | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues | LABORATOIRE THERAMEX (MC) | 2000-05-10 | — | — | EP | disclosed |
| EP-0522152-A1 | LHRH ANTAGONISTS | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 1993-01-13 | — | — | EP | disclosed |
| WO-1992013883-A1 | LHRH ANTAGONISTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | EPHX2 3588/4885CYP2C9 4883/4885CYP2C19 4878/4885 |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | EPHX2 916/4885CYP2C9 4846/4885CYP2C19 4810/4885 |
| US-20250388669-A1 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | TNFRSF9, FCGR3B, FCGR2A | EPHX2 3216/4885CYP2C9 4601/4885CYP2C19 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.